6moe - Revision history

OCA at 06:35, 11 October 2023

OCA — Wed, 11 Oct 2023 06:35:25 GMT

←Older revision		Revision as of 06:35, 11 October 2023
Line 3:		Line 3:
	<StructureSection load='6moe' size='340' side='right'caption='[[6moe]], [[Resolution\|resolution]] 2.09Å' scene=''>		<StructureSection load='6moe' size='340' side='right'caption='[[6moe]], [[Resolution\|resolution]] 2.09Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[6moe]] is a 4 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6MOE OCA]. For a <b>guided tour on the structure components</b> use [~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=6MOE FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[6moe]] is a 4 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] and [https://en.wikipedia.org/wiki/Synthetic_construct Synthetic construct]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6MOE OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6MOE FirstGlance]. <br>
-	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene>, <scene name='pdbligand=EPE:4-(2-HYDROXYETHYL)-1-PIPERAZINE+ETHANESULFONIC+ACID'>EPE</scene>, <scene name='pdbligand=PO4:PHOSPHATE+ION'>PO4</scene></td></tr>	+	</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models\|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution\|Resolution]] 2.091Å</td></tr>
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=6moe FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6moe OCA], [~~http~~://pdbe.org/6moe PDBe], [~~http~~://www.rcsb.org/pdb/explore.do?structureId=6moe RCSB], [~~http~~://www.ebi.ac.uk/pdbsum/6moe PDBsum], [~~http~~://prosat.h-its.org/prosat/prosatexe?pdbcode=6moe ProSAT]</span></td></tr>	+	<tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene>, <scene name='pdbligand=EPE:4-(2-HYDROXYETHYL)-1-PIPERAZINE+ETHANESULFONIC+ACID'>EPE</scene>, <scene name='pdbligand=PO4:PHOSPHATE+ION'>PO4</scene></td></tr>
		+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6moe FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6moe OCA], [https://pdbe.org/6moe PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6moe RCSB], [https://www.ebi.ac.uk/pdbsum/6moe PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6moe ProSAT]</span></td></tr>
	</table>		</table>
	== Disease ==		== Disease ==
-	[~~[http~~://www.uniprot.org/uniprot/EPOR_HUMAN EPOR_HUMAN]] Defects in EPOR are the cause of familial erythrocytosis type 1 (ECYT1) [MIM:[~~http~~://omim.org/entry/133100 133100]]. ECYT1 is an autosomal dominant disorder characterized by increased serum red blood cell mass, elevated hemoglobin and hematocrit, hypersensitivity of erythroid progenitors to erythropoietin, erythropoietin low serum levels, and no increase in platelets nor leukocytes. It has a relatively benign course and does not progress to leukemia.<ref>PMID:8506290</ref> <ref>PMID:8174675</ref> <ref>PMID:8608241</ref>	+	[https://www.uniprot.org/uniprot/EPOR_HUMAN EPOR_HUMAN] Defects in EPOR are the cause of familial erythrocytosis type 1 (ECYT1) [MIM:[https://omim.org/entry/133100 133100]. ECYT1 is an autosomal dominant disorder characterized by increased serum red blood cell mass, elevated hemoglobin and hematocrit, hypersensitivity of erythroid progenitors to erythropoietin, erythropoietin low serum levels, and no increase in platelets nor leukocytes. It has a relatively benign course and does not progress to leukemia.<ref>PMID:8506290</ref> <ref>PMID:8174675</ref> <ref>PMID:8608241</ref>
	== Function ==		== Function ==
-	[~~[http~~://www.uniprot.org/uniprot/EPOR_HUMAN EPOR_HUMAN]] Receptor for erythropoietin. Mediates erythropoietin-induced erythroblast proliferation and differentiation. Upon EPO stimulation, EPOR dimerizes triggering the JAK2/STAT5 signaling cascade. In some cell types, can also activate STAT1 and STAT3. May also activate the LYN tyrosine kinase. Isoform EPOR-T acts as a dominant-negative receptor of EPOR-mediated signaling.	+	[https://www.uniprot.org/uniprot/EPOR_HUMAN EPOR_HUMAN] Receptor for erythropoietin. Mediates erythropoietin-induced erythroblast proliferation and differentiation. Upon EPO stimulation, EPOR dimerizes triggering the JAK2/STAT5 signaling cascade. In some cell types, can also activate STAT1 and STAT3. May also activate the LYN tyrosine kinase. Isoform EPOR-T acts as a dominant-negative receptor of EPOR-mediated signaling.
	<div style="background-color:#fffaf0;">		<div style="background-color:#fffaf0;">
	== Publication Abstract from PubMed ==		== Publication Abstract from PubMed ==
Line 20:		Line 21:
	</div>		</div>
	<div class="pdbe-citations 6moe" style="background-color:#fffaf0;"></div>		<div class="pdbe-citations 6moe" style="background-color:#fffaf0;"></div>
		+
		+	==See Also==
		+	*[[Erythropoietin receptor\|Erythropoietin receptor]]
	== References ==		== References ==
	<references/>		<references/>
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
		+	[[Category: Homo sapiens]]
	[[Category: Large Structures]]		[[Category: Large Structures]]
-	[[Category: ~~Garcia, K C~~]]	+	[[Category: Synthetic construct]]
-	[[Category: ~~Jude, K M~~]]	+	[[Category: Garcia KC]]
-	[[Category: ~~Mohan, K~~]]	+	[[Category: Jude KM]]
-	[[Category: ~~Biosynthetic protein]]~~	+	[[Category: Mohan K]]
-	~~[[Category: Complex]]~~	+
-	~~[[Category: Darpin]]~~	+
-	~~[[Category: Receptor~~]]	+

OCA at 06:15, 12 June 2019

OCA — Wed, 12 Jun 2019 06:15:59 GMT

←Older revision		Revision as of 06:15, 12 June 2019
Line 11:		Line 11:
	== Function ==		== Function ==
	[[http://www.uniprot.org/uniprot/EPOR_HUMAN EPOR_HUMAN]] Receptor for erythropoietin. Mediates erythropoietin-induced erythroblast proliferation and differentiation. Upon EPO stimulation, EPOR dimerizes triggering the JAK2/STAT5 signaling cascade. In some cell types, can also activate STAT1 and STAT3. May also activate the LYN tyrosine kinase. Isoform EPOR-T acts as a dominant-negative receptor of EPOR-mediated signaling.		[[http://www.uniprot.org/uniprot/EPOR_HUMAN EPOR_HUMAN]] Receptor for erythropoietin. Mediates erythropoietin-induced erythroblast proliferation and differentiation. Upon EPO stimulation, EPOR dimerizes triggering the JAK2/STAT5 signaling cascade. In some cell types, can also activate STAT1 and STAT3. May also activate the LYN tyrosine kinase. Isoform EPOR-T acts as a dominant-negative receptor of EPOR-mediated signaling.
		+	<div style="background-color:#fffaf0;">
		+	== Publication Abstract from PubMed ==
		+	Although tunable signaling by G protein-coupled receptors can be exploited through medicinal chemistry, a comparable pharmacological approach has been lacking for the modulation of signaling through dimeric receptors, such as those for cytokines. We present a strategy to modulate cytokine receptor signaling output by use of a series of designed C2-symmetric cytokine mimetics, based on the designed ankyrin repeat protein (DARPin) scaffold, that can systematically control erythropoietin receptor (EpoR) dimerization orientation and distance between monomers. We sampled a range of EpoR geometries by varying intermonomer angle and distance, corroborated by several ligand-EpoR complex crystal structures. Across the range, we observed full, partial, and biased agonism as well as stage-selective effects on hematopoiesis. This surrogate ligand strategy opens access to pharmacological modulation of therapeutically important cytokine and growth factor receptor systems.
		+
		+	Topological control of cytokine receptor signaling induces differential effects in hematopoiesis.,Mohan K, Ueda G, Kim AR, Jude KM, Fallas JA, Guo Y, Hafer M, Miao Y, Saxton RA, Piehler J, Sankaran VG, Baker D, Garcia KC Science. 2019 May 24;364(6442). pii: 364/6442/eaav7532. doi:, 10.1126/science.aav7532. Epub 2019 May 23. PMID:31123111<ref>PMID:31123111</ref>
		+
		+	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
		+	</div>
		+	<div class="pdbe-citations 6moe" style="background-color:#fffaf0;"></div>
	== References ==		== References ==
	<references/>		<references/>

OCA at 22:47, 5 June 2019

OCA — Wed, 05 Jun 2019 22:47:39 GMT

←Older revision		Revision as of 22:47, 5 June 2019
Line 1:		Line 1:
-	'''Unreleased structure'''

-	~~The entry~~ 6moe is ~~ON HOLD until Paper Publication~~	+	==Monomeric DARPin E2 complex with EpoR==
-		+	<StructureSection load='6moe' size='340' side='right'caption='[[6moe]], [[Resolution\|resolution]] 2.09Å' scene=''>
-	~~Authors~~:	+	== Structural highlights ==
-		+	<table><tr><td colspan='2'>[[6moe]] is a 4 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6MOE OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6MOE FirstGlance]. <br>
-	~~Description~~:	+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene>, <scene name='pdbligand=EPE:4-(2-HYDROXYETHYL)-1-PIPERAZINE+ETHANESULFONIC+ACID'>EPE</scene>, <scene name='pdbligand=PO4:PHOSPHATE+ION'>PO4</scene></td></tr>
-	[[Category: ~~Unreleased~~ Structures]]	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6moe FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6moe OCA], [http://pdbe.org/6moe PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6moe RCSB], [http://www.ebi.ac.uk/pdbsum/6moe PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6moe ProSAT]</span></td></tr>
		+	</table>
		+	== Disease ==
		+	[[http://www.uniprot.org/uniprot/EPOR_HUMAN EPOR_HUMAN]] Defects in EPOR are the cause of familial erythrocytosis type 1 (ECYT1) [MIM:[http://omim.org/entry/133100 133100]]. ECYT1 is an autosomal dominant disorder characterized by increased serum red blood cell mass, elevated hemoglobin and hematocrit, hypersensitivity of erythroid progenitors to erythropoietin, erythropoietin low serum levels, and no increase in platelets nor leukocytes. It has a relatively benign course and does not progress to leukemia.<ref>PMID:8506290</ref> <ref>PMID:8174675</ref> <ref>PMID:8608241</ref>
		+	== Function ==
		+	[[http://www.uniprot.org/uniprot/EPOR_HUMAN EPOR_HUMAN]] Receptor for erythropoietin. Mediates erythropoietin-induced erythroblast proliferation and differentiation. Upon EPO stimulation, EPOR dimerizes triggering the JAK2/STAT5 signaling cascade. In some cell types, can also activate STAT1 and STAT3. May also activate the LYN tyrosine kinase. Isoform EPOR-T acts as a dominant-negative receptor of EPOR-mediated signaling.
		+	== References ==
		+	<references/>
		+	__TOC__
		+	</StructureSection>
		+	[[Category: Large Structures]]
		+	[[Category: Garcia, K C]]
		+	[[Category: Jude, K M]]
		+	[[Category: Mohan, K]]
		+	[[Category: Biosynthetic protein]]
		+	[[Category: Complex]]
		+	[[Category: Darpin]]
		+	[[Category: Receptor]]

OCA at 05:27, 31 October 2018

OCA — Wed, 31 Oct 2018 05:27:21 GMT

←Older revision		Revision as of 05:27, 31 October 2018
Line 1:		Line 1:
	'''Unreleased structure'''		'''Unreleased structure'''

-	The entry 6moe is ON HOLD	+	The entry 6moe is ON HOLD until Paper Publication

	Authors:		Authors:

OCA: Protected "6moe" [edit=sysop:move=sysop]

OCA — Wed, 10 Oct 2018 06:37:35 GMT

Protected "6moe" [edit=sysop:move=sysop]

←Older revision

Revision as of 06:37, 10 October 2018

OCA: New page: '''Unreleased structure''' The entry 6moe is ON HOLD Authors: Description: Category: Unreleased Structures

OCA — Wed, 10 Oct 2018 06:37:34 GMT

New page: '''Unreleased structure''' The entry 6moe is ON HOLD Authors: Description: Category: Unreleased Structures

New page

'''Unreleased structure'''

The entry 6moe is ON HOLD

Authors:

Description:
[[Category: Unreleased Structures]]